Plegridy 125mcg Injection

About

Peginterferon beta-1a is a pegylated form of interferon beta-1a, a cytokine naturally produced by the body, primarily used in the treatment of relapsing forms of multiple sclerosis (MS). Pegylation extends the half-life of the interferon, allowing for less frequent dosing. Its mechanism of action in MS is not fully understood but is thought to involve immunomodulatory and anti-inflammatory effects. It reduces the frequency of relapses and slows the progression of disability by modulating the immune response, reducing inflammation in the central nervous system, and potentially protecting nerve cells from damage. This medication helps to decrease the number of new brain lesions seen on MRI scans, indicating its effectiveness in managing disease activity. It represents a crucial therapeutic option for patients seeking to manage their disease progression and improve their quality of life.

Uses

• Treatment of relapsing forms of multiple sclerosis (MS).
• Includes clinically isolated syndrome (CIS).
• Relapsing-remitting multiple sclerosis (RRMS).
• Active secondary progressive multiple sclerosis (SPMS).

Directions For Use

Administer subcutaneously every two weeks. Follow healthcare provider's instructions for injection technique and site rotation.

Benefits

• Reduces frequency of MS relapses.
• Slows progression of disability in MS.
• Decreases new brain lesions on MRI.
• Convenient bi-weekly dosing schedule.
• Immunomodulatory and anti-inflammatory effects.
• Helps manage disease activity in relapsing MS.

Side Effects

• Injection site reactions (redness, pain, swelling)
• Flu-like symptoms (fever, chills, headache, muscle aches)
• Fatigue
• Nausea
• Diarrhea
• Elevated liver enzymes
• Leukopenia
• Thrombocytopenia
• Depression
• Seizures
• Thyroid dysfunction
• Allergic reactions

Safety Measures

• Alcohol - Use alcohol cautiously; it may exacerbate liver enzyme elevations, a known side effect of interferon therapy.
• Pregnancy - Use only if the potential benefit justifies the potential risk to the fetus; consult a doctor.
• Breastfeeding - Exercise caution; it is unknown if peginterferon beta-1a is excreted in human milk.
• Liver - Monitor liver function tests regularly; use with caution in patients with pre-existing hepatic impairment.
• Kidney - Use with caution in patients with severe renal impairment; no specific dose adjustment guidelines are available.
• Lung - Monitor for pulmonary arterial hypertension, a rare but serious adverse event reported with interferon beta products.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.